A Research Guide for
Liver Disease

Old name: Non-Alcoholic Fatty Liver Disease (NAFLD)
New name: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

The new name reflects the fact that this condition is driven by metabolic factors — insulin resistance, excess weight, elevated blood sugar, abnormal lipids, or high blood pressure — rather than simply defining it by the absence of alcohol. A diagnosis of MASLD requires evidence of liver fat (steatosis) plus at least one cardiometabolic risk factor.

Old name: Non-Alcoholic Steatohepatitis (NASH)
New name: Metabolic Dysfunction-Associated Steatohepatitis (MASH)

MASH is the more aggressive form: fat in the liver plus active inflammation and liver cell damage (ballooning). MASH is the stage where fibrosis tends to progress, and it is the stage where the new FDA-approved medications are indicated. Not everyone with MASLD develops MASH — many people have simple steatosis that never progresses.

MetALD (Metabolic and Alcohol-Related Liver Disease) is a new category for people who have both metabolic risk factors and moderate alcohol intake (defined as roughly 140–350 grams per week for women and 210–420 grams per week for men). This recognizes that metabolic and alcohol-related liver injury often coexist and compound each other. If you fall into this category, addressing both the metabolic factors and reducing alcohol are important.

An increasingly recognized pattern: approximately 10–20% of people with MASLD have a normal or near-normal body mass index (BMI <25 kg/m²). This is sometimes called “lean MASLD” (previously “lean NAFLD”). It is real, it is not rare, and it can progress to fibrosis and cirrhosis just as in heavier patients.

• Why it happens: Lean MASLD is driven by the same metabolic dysfunction — insulin resistance, elevated visceral fat (even with normal total body weight), genetic predisposition (especially PNPLA3 and TM6SF2 variants), and dyslipidemia. Asian populations are disproportionately affected.
• Why it matters: Because body weight is normal, lean MASLD is frequently missed. Physicians may not check liver enzymes or imaging in a slim patient, and the patient may not be screened for metabolic risk factors.
• What to do: The same metabolic interventions apply: manage insulin resistance, exercise regularly, improve diet quality, and control lipids. Weight loss per se may be less relevant, but reducing visceral fat through exercise and dietary change remains beneficial. Fibrosis staging (FIB-4, FibroScan) should be pursued if liver enzymes are elevated, regardless of BMI.

• F0: No fibrosis. Normal liver tissue.
• F1: Mild fibrosis. Scarring around the portal tracts (the “intersections” of the liver). Usually no symptoms and an excellent outlook.
• F2: Moderate fibrosis. Scarring extends outward and begins to bridge between portal tracts. This is the stage where the new approved medications become indicated.
• F3: Advanced fibrosis. Bridging fibrosis is extensive, distorting liver architecture. Significant risk of progressing to cirrhosis without intervention.
• F4: Cirrhosis. The liver is extensively scarred, with nodules replacing normal tissue. This is subdivided into compensated (still functioning) and decompensated (complications present).

Several non-invasive tools can assess fibrosis without a liver biopsy. These should be discussed with your hepatologist or gastroenterologist:

• FIB-4 score: A simple calculation using your age, platelet count, and two liver enzymes (AST and ALT) from a routine blood test. A score below 1.3 suggests minimal fibrosis; above 2.67 suggests advanced fibrosis. It is a screening tool, not a definitive answer, but it is free and available from any blood panel.
• FibroScan (transient elastography): A painless, non-invasive scan that measures liver stiffness by sending a vibration pulse through the liver. Takes about 10 minutes. Results are reported in kilopascals (kPa): below 7 kPa is generally normal; above 12–14 kPa suggests cirrhosis. FibroScan also measures the Controlled Attenuation Parameter (CAP), which quantifies liver fat.
• ELF test (Enhanced Liver Fibrosis): A blood test measuring three markers of fibrosis activity. More accurate than FIB-4 at distinguishing intermediate stages.
• MR elastography (MRE): An MRI-based technique that is the most accurate non-invasive tool for staging fibrosis. Often used when other tests are inconclusive or when precise staging is needed for treatment decisions or clinical trials.
• Liver biopsy: The traditional reference standard. A small needle removes a tiny sample of liver tissue for microscopic examination. Still used when non-invasive tests are inconclusive, when an alternative diagnosis is suspected, or to confirm the degree of inflammation (important for treatment decisions). The procedure carries a small risk of pain and bleeding.

Standard blood work includes a panel often called “liver function tests,” and understanding the main numbers helps you follow your own care. A few key points:

• ALT and AST are enzymes released when liver cells are inflamed or injured. They are useful, but with one big caveat: normal ALT and AST do not rule out advanced scarring. Enzymes often settle back toward normal even as fibrosis quietly advances, which is exactly why staging tools like FIB-4 and FibroScan matter more than enzymes alone for judging risk.
• Alkaline phosphatase (ALP) and GGT rise more with problems in the bile-drainage system; the pattern of which enzymes are up helps point toward the cause.
• Bilirubin reflects the liver’s ability to process waste; a rise can cause jaundice (yellowing) and is one of the markers that signals more advanced disease.
• Albumin and INR (clotting) measure how well the liver is doing its manufacturing jobs — making proteins and clotting factors. Low albumin or a high INR suggest reduced liver function.
• Platelet count is a quietly important number: a falling platelet count can be an early clue to increased pressure in the liver’s veins (portal hypertension) and is part of the FIB-4 score.

You do not need to memorize cutoffs — the useful habit is to ask your doctor, “What do my liver numbers and my FIB-4 suggest about my stage, and are they trending better or worse?” The trend over time is often more informative than any single result.

Fat has accumulated in liver cells, typically because of insulin resistance, excess caloric intake, or metabolic syndrome. The liver is not inflamed or scarred at this stage. Liver enzymes may be normal or only mildly elevated. Many people remain at this stage indefinitely and never develop significant liver problems.

Yes — fully and reliably. Weight loss of even 3–5% of body weight can meaningfully reduce liver fat. Weight loss of 7–10% can eliminate steatosis entirely in many people. The liver heals completely at this stage because there is no scar tissue to contend with.

• Get a baseline fibrosis assessment (FIB-4 from blood work, and ideally a FibroScan) to confirm you are truly at an early stage.
• Address cardiovascular risk factors aggressively — heart disease is the number one cause of death in people with MASLD, not liver disease.
• Begin sustainable dietary changes (the Mediterranean diet has the strongest evidence) and regular physical activity.
• Minimize or eliminate alcohol — even moderate drinking compounds metabolic liver injury.
• If you have type 2 diabetes or prediabetes, ensure it is well managed. Insulin resistance drives fat accumulation in the liver.

The primary risk is cardiovascular disease, not liver disease. People with MASLD have a significantly elevated risk of heart attack and stroke. A smaller percentage — roughly 20–30% — will develop MASH with inflammation, which opens the door to progressive fibrosis. Identifying who will progress is an active area of research.

• What is my FIB-4 score, and does it suggest I need further fibrosis testing?
• Should I get a FibroScan to establish a baseline?
• What are my cardiovascular risk factors, and are they being managed?
• Am I a candidate for a GLP-1 receptor agonist for weight management?
• How often should I be monitored, and what tests should I expect?

The liver is under active attack. Inflammation drives the production of scar tissue. Without intervention, a significant proportion of patients with MASH will develop progressive fibrosis over years to decades. However, the rate of progression varies enormously — some people progress slowly or not at all, while others develop cirrhosis within 10–15 years.

MASH is typically diagnosed when liver enzymes are persistently elevated (particularly ALT), imaging shows liver fat, and either a biopsy confirms inflammation and ballooning or non-invasive tests suggest it. Symptoms may still be absent or limited to fatigue and vague right-upper-abdominal discomfort.

Yes. The inflammation of MASH can resolve completely, and early fibrosis (F1) can reverse. Weight loss of 7–10% of body weight has been shown to resolve MASH in the majority of patients. This is the critical window — the period when action has the most impact on long-term outcomes.

• Confirm your fibrosis stage with FibroScan or MR elastography — this determines the urgency.
• Commit to a sustained weight loss program. The 7–10% target is well established in clinical trials. Even 5% is beneficial.
• Discuss whether you are a candidate for the newly approved medications (resmetirom or semaglutide) if fibrosis is F2 or higher.
• Manage all metabolic comorbidities: diabetes, hypertension, dyslipidemia.
• Eliminate or sharply reduce alcohol.
• Establish a monitoring schedule with your hepatologist or gastroenterologist.

The primary liver risk is progression to significant fibrosis (F2–F3) and eventually cirrhosis. Cardiovascular disease remains the leading cause of death overall. The combination of active inflammation and metabolic risk factors creates a dual threat that requires attention to both the liver and the heart.

• What is my current fibrosis stage? Is it F0–F1, or has it progressed to F2 or beyond?
• Am I a candidate for resmetirom or semaglutide?
• Should I be referred to a hepatologist?
• What weight loss target should I aim for, and can you refer me to a structured program?
• How often should I repeat fibrosis testing to track progression or improvement?

The liver is actively scarring. Blood flow through the liver is beginning to be affected. The risk of progressing to cirrhosis within the next 5–10 years is real and significant without treatment. However — and this is the critical point — fibrosis at this stage can still regress with sustained intervention. Clinical trials of both resmetirom and semaglutide showed fibrosis regression in a meaningful proportion of patients at F2–F3.

Often, yes. Fibrosis regression has been demonstrated in multiple clinical trials with weight loss of 10% or more, with resmetirom, and with semaglutide. The liver’s capacity to remodel scar tissue is real but requires sustained effort — months to years of consistent treatment. This is not a stage where reversal happens quickly, but it is a stage where reversal is still achievable.

• Be under the care of a hepatologist or experienced gastroenterologist — this stage warrants specialist oversight.
• Discuss FDA-approved pharmacotherapy: resmetirom (Rezdiffra) and/or semaglutide (Wegovy).
• Pursue aggressive lifestyle modification with a target of 10%+ weight loss.
• Ensure all metabolic conditions are optimally managed.
• Get a baseline assessment for portal hypertension if F3 is confirmed (platelet count, liver stiffness).
• Monitor fibrosis at regular intervals (typically annually) to track response to treatment.
• Complete elimination of alcohol is strongly recommended at this stage.

The dominant liver risk is progression to cirrhosis. Cardiovascular risk remains high. Some patients at F3 may already have early portal hypertension. The window to prevent cirrhosis is narrowing but still open — this is arguably the most important stage for aggressive intervention.

• Am I F2 or F3? How confident are we in the staging?
• Should I start resmetirom, semaglutide, or both?
• Do I need to be screened for varices (dilated veins) at this point?
• What is my platelet count, and does it suggest early portal hypertension?
• How will we track whether my fibrosis is improving or worsening?
• Am I a candidate for a clinical trial?

The liver has reached F4 fibrosis. Normal liver tissue has been replaced by scar tissue and regenerative nodules. Blood flow through the liver is significantly impaired, leading to increased pressure in the portal vein (portal hypertension). Despite all this, the liver is still producing enough protein, clearing enough toxin, and maintaining enough function to avoid the major complications of liver failure — for now.

Partial regression is possible. Studies of patients with compensated cirrhosis from hepatitis C who achieved viral cure showed meaningful fibrosis regression in a significant proportion. Similarly, sustained weight loss in MASH-related cirrhosis can lead to some improvement. However, complete reversal to a normal liver is unlikely. The goal at this stage shifts to preventing decompensation, screening for liver cancer, and maintaining function.

• Liver cancer screening: Ultrasound plus AFP blood test every 6 months. This is non-negotiable and potentially life-saving.
• Variceal screening: Upper endoscopy (EGD) to check for esophageal or gastric varices. If varices are found, preventive treatment (beta-blockers or endoscopic banding) reduces the risk of life-threatening bleeding.
• Bone density screening: Cirrhosis increases osteoporosis risk.
• Continue all lifestyle measures and pharmacotherapy as tolerated.
• Avoid NSAIDs (ibuprofen, naproxen) — they can cause kidney injury and bleeding in cirrhosis.
• Minimize or eliminate medications processed by the liver; review all medications including over-the-counter drugs with your hepatologist.
• Limit sodium intake to help prevent fluid retention.
• Ensure vaccinations are up to date: hepatitis A, hepatitis B, pneumococcal, influenza, COVID-19.

The two main risks are decompensation (the development of complications like ascites, variceal bleeding, or encephalopathy) and liver cancer (HCC). The annual risk of decompensation in compensated cirrhosis is roughly 5–7%. The annual risk of developing HCC is 1–4%. Both risks make regular screening and close follow-up essential.

• Am I on a 6-month liver cancer screening schedule? When is my next ultrasound and AFP?
• Have I been screened for varices? Do I need to be on a beta-blocker?
• What is my MELD score, and what does it mean?
• Should I be evaluated for liver transplant at this point?
• Are there any medications I should stop taking?
• What signs of decompensation should I watch for?

The liver has crossed a threshold. It can no longer adequately filter toxins, produce clotting factors, regulate fluid balance, or fight infection. Patients are at high risk for hospitalization, infection, kidney failure, and death. Median survival after the first decompensation event without transplant is roughly 2 years, though this varies widely with the type and severity of complications and how well they are managed.

In some cases, yes — partially. Patients whose cirrhosis has a treatable underlying cause (such as alcohol-related liver disease in someone who achieves sustained sobriety, or hepatitis C with antiviral cure) can sometimes “re-compensate” — returning from decompensated to compensated status. This is not guaranteed, but it does happen. For MASH-related cirrhosis, aggressive weight loss and metabolic management can stabilize the disease. For many patients, however, transplant evaluation is appropriate and should not be delayed.

• Transplant evaluation: If eligible, begin the evaluation process. This takes weeks to months and should be started before the situation becomes urgent.
• Manage complications aggressively: Ascites (diuretics, sodium restriction, paracentesis), encephalopathy (lactulose and rifaximin), variceal bleeding (band ligation, beta-blockers, TIPS if needed), infections (low threshold for antibiotics).
• Never stop lactulose without medical guidance. Lactulose prevents the buildup of ammonia, which causes confusion and can progress to coma. Stopping it abruptly is dangerous.
• Continue liver cancer screening every 6 months.
• Complete sobriety from alcohol is essential.
• Ensure adequate nutrition — malnutrition is common and dangerous in decompensated cirrhosis. An experienced dietitian is important.

• Should I be referred to a transplant center for evaluation?
• What is my current MELD score, and what does it mean for transplant timing?
• Is TIPS (transjugular intrahepatic portosystemic shunt) appropriate for me?
• Am I on the right combination of lactulose and rifaximin for encephalopathy?
• What signs mean I should go to the emergency room immediately?
• Is palliative care appropriate alongside active treatment?

Cancer has arisen in the liver, almost always in a background of cirrhosis or advanced fibrosis. HCC grows within the liver and can spread to other organs. The treatment and prognosis depend heavily on the size and number of tumors, whether the underlying liver function is preserved, and whether the cancer has spread beyond the liver.

Yes. Early-stage HCC has multiple curative options: surgical resection, ablation (destroying the tumor with heat or cold), and liver transplant (which treats both the cancer and the underlying cirrhosis). For intermediate and advanced HCC, locoregional therapies (TACE, TARE/Y-90) and systemic therapies (immunotherapy combinations, targeted drugs) can control the disease and extend life significantly. A multidisciplinary tumor board — hepatologist, transplant surgeon, interventional radiologist, and oncologist — should guide all treatment decisions.

• Ensure your case is reviewed by a multidisciplinary liver tumor board.
• Get complete staging: CT or MRI of the liver with contrast, chest CT, AFP and other tumor markers.
• Discuss all treatment options: resection, ablation, transplant, locoregional therapy, systemic therapy.
• If you are a transplant candidate, ensure you are listed promptly — HCC exception points on the transplant list can give you priority.
• Seek a second opinion at a major liver center if any complexity exists.

• What stage is my liver cancer, and what staging system is being used (BCLC, Milan)?
• Am I a candidate for curative treatment — resection, ablation, or transplant?
• If transplant is an option, what is the timeline and how do exception points work?
• What locoregional or systemic therapies are appropriate if surgery is not an option?
• Are there clinical trials I should consider?
• Has my case been discussed at a multidisciplinary tumor board?

Clinical trials have established clear dose-response thresholds for weight loss in MASLD/MASH:

• 3–5% weight loss: Reduces liver fat (steatosis). A meaningful first step.
• 7–10% weight loss: Resolves MASH (inflammation and ballooning) in the majority of patients. This is the target that changes the disease trajectory.
• 10%+ weight loss: Can reverse fibrosis in many patients. This is the target for patients with F2–F3 fibrosis.

The challenge is achieving and sustaining this weight loss over time. This is where structured programs, GLP-1 medications, and in some cases bariatric surgery become relevant.

The Mediterranean diet has the strongest evidence base for liver disease. Its core features:

• Rich in vegetables, fruits, whole grains, legumes, nuts, and olive oil as the primary fat
• Moderate fish and poultry
• Limited red meat, processed foods, refined sugars, and saturated fat
• No or minimal sugar-sweetened beverages — fructose is particularly harmful to the liver

The Mediterranean diet reduces liver fat, inflammation, and cardiovascular risk simultaneously. An oncology or hepatology dietitian can help tailor the approach to individual needs and preferences.

Exercise reduces liver fat and inflammation even without weight loss. Both aerobic exercise (walking, cycling, swimming) and resistance training (weights) are beneficial. The general recommendation is at least 150 minutes per week of moderate-intensity aerobic activity. Start where you are and build gradually — any increase from baseline is beneficial. For patients with cirrhosis, exercise should be tailored to avoid injury, and a physical therapist experienced with liver disease can help design a safe program.

For patients with MASLD/MASH, there is no safe threshold of alcohol consumption that has been established. Alcohol and metabolic liver injury compound each other. The safest approach is complete elimination, especially for anyone with fibrosis stage F2 or higher. For patients with cirrhosis, alcohol abstinence is essential and non-negotiable.

Multiple large studies have consistently shown that regular coffee consumption — roughly 3 or more cups per day — is associated with reduced liver fibrosis, lower risk of liver cancer, and slower disease progression. This appears to be a real biological effect, not a statistical artifact. Both caffeinated and decaffeinated coffee show benefit, though caffeinated is better studied. Coffee is one of the rare dietary factors where the evidence is strong and the intervention is pleasant.

Alongside the things that help, it is worth knowing the common, avoidable things that quietly harm the liver — especially once you have fibrosis or cirrhosis. None of this is about fear; it is about a few simple habits.

• Alcohol. There is no “safe” amount once you have significant liver disease, and even moderate drinking compounds metabolic injury. If you have F2 fibrosis or beyond, abstinence is strongly advised. If cutting down is hard, that is common and treatable — tell your team.
• Pain relievers. With cirrhosis, avoid NSAIDs (ibuprofen, naproxen, aspirin for pain) — they can harm the kidneys and increase bleeding risk. Acetaminophen (paracetamol) is generally the safer choice but should be limited (often to no more than 2 grams a day in cirrhosis) — confirm your limit with your doctor.
• Supplements and herbal products. “Natural” does not mean safe for the liver. Some supplements and herbal remedies (and even high-dose vitamin A or green-tea extract) can cause liver injury. Tell your team about everything you take, and be skeptical of products promising to “detox” or “cleanse” the liver.
• New medications. Because the liver processes most drugs, always remind any new prescriber that you have liver disease, and check before starting something new — doses sometimes need adjusting.
• Infections. Vaccinations matter: hepatitis A and B, pneumococcal, influenza, and COVID-19 are recommended, because infections are riskier with a damaged liver. In cirrhosis, fever with chills is a reason to seek care promptly.
• Raw shellfish. People with cirrhosis should avoid raw or undercooked shellfish, which can carry a bacterium (Vibrio) that causes severe, sometimes fatal infections in people with liver disease.

A good rule of thumb: before taking anything new — medicine, supplement, or remedy — ask your liver team or pharmacist, “Is this safe for my liver?”

What it is: Resmetirom is a selective thyroid hormone receptor beta (THR-β) agonist taken as a daily oral pill. It was approved by the FDA in March 2024 for MASH with moderate to advanced fibrosis (F2–F3), making it the first drug ever approved specifically for this condition.

How it works: It activates thyroid hormone signaling specifically in the liver, which reduces liver fat, lowers harmful lipids, and decreases inflammation without causing the systemic effects of thyroid hormone excess.

The evidence (MAESTRO-NASH trial): In the phase 3 MAESTRO-NASH trial, resmetirom at the 100 mg dose achieved MASH resolution in approximately 30% of patients (vs. 10% placebo) and fibrosis improvement by at least one stage in approximately 26% of patients (vs. 14% placebo) at 52 weeks. It also significantly improved liver enzymes, liver fat, and lipid profiles.

Dosing: Started at 80 mg daily for the first 3 months, then increased to 100 mg daily. Taken with food.

Side effects: Generally well tolerated. The most common side effects are diarrhea and nausea (usually mild and transient). Thyroid function should be monitored. It should not be used in patients with decompensated cirrhosis.

Important note: The accelerated approval was based on surrogate endpoints (MASH resolution and fibrosis improvement on biopsy). A confirmatory trial assessing clinical outcomes (progression to cirrhosis, liver-related events) is underway.

What it is: Semaglutide is a GLP-1 receptor agonist given as a weekly subcutaneous injection. Originally developed for type 2 diabetes (as Ozempic) and obesity (as Wegovy), it received an expanded FDA indication for MASH with significant fibrosis based on the ESSENCE trial results.

How it works: Semaglutide reduces appetite, promotes weight loss, improves insulin sensitivity, and has direct anti-inflammatory effects in the liver. Its impact on liver disease comes through both weight loss and direct hepatic effects.

The evidence (ESSENCE trial): The phase 3 ESSENCE trial showed that semaglutide 2.4 mg weekly achieved fibrosis improvement without worsening of MASH in approximately 37% of patients (vs. 23% placebo), and MASH resolution without worsening of fibrosis in approximately 62% of patients (vs. 34% placebo). The average weight loss was approximately 10–13%.

Dosing: Titrated up slowly over 16–20 weeks to a target dose of 2.4 mg weekly via subcutaneous injection.

Side effects: Nausea, vomiting, diarrhea, and constipation are common, particularly during dose escalation, and usually improve. More serious but rare risks include pancreatitis and gallbladder disease. It should not be used in patients with a personal or family history of medullary thyroid cancer or MEN2 syndrome.

The choice between resmetirom and semaglutide depends on the individual patient’s profile:

• Resmetirom may be preferred for patients who are lean or only mildly overweight, who do not tolerate injections, or who have significant dyslipidemia (it substantially lowers LDL cholesterol and triglycerides).
• Semaglutide may be preferred for patients with significant obesity, type 2 diabetes, or those who want the cardiovascular benefits that GLP-1 agonists provide.
• Combination therapy: Some hepatologists are beginning to use both drugs together, as they work through different mechanisms. This approach is logical but not yet supported by completed clinical trials of the combination specifically.

These decisions should be made with a hepatologist familiar with the latest guidance.

Pioglitazone is a thiazolidinedione approved for type 2 diabetes. It has the longest track record of any medication studied in MASH, with multiple trials showing improvement in liver inflammation, ballooning, and steatosis. Some trials have also shown fibrosis improvement. It works by improving insulin sensitivity and redistributing fat away from the liver.

Limitations: It causes weight gain (typically 3–5 kg), can worsen heart failure, and carries a small increased risk of bone fractures and bladder cancer with long-term use. It is most appropriate for patients with MASH who also have type 2 diabetes or significant insulin resistance, when the newer approved medications are not accessible.

Vitamin E (alpha-tocopherol, 800 IU daily) improved MASH on biopsy in the landmark PIVENS trial. It reduces oxidative stress and inflammation in the liver. The AASLD has recommended it as a treatment option for non-diabetic adults with biopsy-confirmed MASH.

Limitations: Concerns about a possible small increase in prostate cancer risk at high doses and a possible increase in hemorrhagic stroke have tempered enthusiasm. It has not been shown to improve fibrosis. It is most appropriate for non-diabetic patients with active MASH (NAS score ≥4) who cannot access resmetirom or semaglutide.

Statins are safe in patients with liver disease and should not be withheld because of fatty liver or mildly elevated liver enzymes. This is one of the most important messages in liver medicine, because cardiovascular disease is the leading cause of death in MASLD, and statins are the most effective tool for reducing that risk. Studies suggest statins may also have a direct protective effect on the liver, reducing fibrosis progression and liver cancer risk.

Exception: Statins should be used with caution in decompensated cirrhosis. In compensated cirrhosis and all earlier stages, they should be used as indicated for cardiovascular risk.

Metformin does not improve liver histology in MASH and is not recommended as a liver-specific treatment. However, it remains the first-line drug for type 2 diabetes, and many patients with MASH also have diabetes. In that setting, metformin should be continued for its metabolic benefits. It does not worsen liver disease and is safe to use.

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) are diabetes drugs that have shown promise in reducing liver fat and improving liver enzymes in several studies. They also have cardiovascular and kidney protective effects. While not yet approved for liver disease specifically, they are an attractive option for patients with MASH who also have type 2 diabetes, heart failure, or chronic kidney disease. Several trials are ongoing.

Berberine is a plant alkaloid found in goldenseal, Oregon grape, and several traditional Chinese and Ayurvedic herbs. It has been studied for its effects on metabolic syndrome, insulin resistance, and liver fat.

• Key evidence: A meta-analysis of 10 randomized controlled trials (811 patients) published in the Journal of Translational Medicine (2024) found that berberine supplementation produced significant improvements in ALT, AST, GGT, lipid profiles (total cholesterol, LDL, triglycerides), HOMA-IR (a measure of insulin resistance), and BMI compared to controls.
• Evidence quality: Rated HIGH by GRADE criteria in the meta-analysis.
• Mechanism: Berberine activates AMPK (a cellular energy sensor), improves insulin signaling, reduces hepatic fat synthesis, and has anti-inflammatory properties.
• Limitations: Most individual trials were conducted in China with relatively short follow-up periods. No histological (biopsy) endpoints were assessed — improvements were measured by blood tests and imaging. Gastrointestinal side effects (diarrhea, constipation, nausea) are common. Berberine can interact with medications metabolized by CYP enzymes.
• Source: PMC10908013.

EMERGING — Strong meta-analytic signal for metabolic and liver enzyme improvements in MASLD. Discuss with your hepatologist, especially regarding drug interactions.

Silymarin is the active extract of milk thistle (Silybum marianum), one of the most widely used herbal supplements for liver conditions. It has antioxidant and anti-inflammatory properties.

• Key evidence: A meta-analysis of 26 randomized controlled trials (2,375 patients) published in Annals of Hepatology (2023) found that silymarin significantly improved hepatic steatosis (fat accumulation; OR 3.25 favoring silymarin), fatty liver index/score, and liver transaminases (ALT and AST) compared to controls.
• Critical clarification: The meta-analysis showed improvement in steatosis (liver fat), not fibrosis. The study explicitly stated that fibrosis was not evaluated due to limited histological data across the included trials. Do not confuse fat reduction with scar reduction — these are different outcomes.
• Limitations: Trial quality was variable. Most trials used different silymarin formulations and doses, making direct comparisons difficult. Long-term outcomes (progression to cirrhosis, liver-related events) were not assessed.
• Source: PubMed 38579127.

EMERGING — Evidence supports steatosis improvement and liver enzyme reduction. Fibrosis effects are unknown. Generally well tolerated.

Artichoke leaf extract (Cynara scolymus) contains cynarin and chlorogenic acid, which have been studied for hepatoprotective and lipid-lowering effects.

• Key evidence: Multiple small double-blind randomized controlled trials have evaluated artichoke leaf extract in NAFLD/MASLD patients:
  • Rangboo 2016: 60 patients with biopsy-confirmed NASH, 2,700 mg/day for 8 weeks, found significant reductions in ALT, AST, total cholesterol, and triglycerides compared to placebo.
  • A second pilot RCT (2018): 100 NAFLD patients, 600 mg/day, showed improved liver ultrasound parameters.
• Limitations: All available trials are small (60–100 patients) and short in duration (8–12 weeks). No long-term data, no fibrosis endpoints, and no large multicenter confirmatory trials. Dose-response relationships are not well established.

EMERGING — Preliminary signals from small trials. Larger and longer studies are needed before this can be recommended with confidence.

The gut-liver axis is a major area of research in liver disease. Gut bacteria produce metabolites that travel directly to the liver via the portal vein, and alterations in the gut microbiome (dysbiosis) are linked to MASLD/MASH progression.

• Key evidence: A probiotics-focused meta-analysis published in Frontiers in Nutrition (2024) analyzed 37 randomized controlled trials (1,921 patients), of which 23 specifically evaluated probiotic supplementation. Probiotics were associated with improvements in liver enzymes (ALT, AST), lipid profiles, and markers of insulin resistance.
• Mechanism: Probiotics may reduce intestinal permeability (“leaky gut”), decrease bacterial endotoxin translocation to the liver, and modulate inflammatory cytokines.
• Limitations: The trials used a wide variety of probiotic strains, doses, and durations, making it difficult to identify the optimal formulation. Most trials were short-term. No fibrosis or hard clinical endpoints were assessed. The gut microbiome is highly individual, and what works for one person may not work for another.
• Source: Frontiers in Nutrition 2024.

EMERGING — Consistent signal across multiple trials for enzyme and metabolic improvements. Optimal strains and doses remain unclear.

N-acetylcysteine (NAC) is a precursor to glutathione, the liver’s primary antioxidant. It is well established as the antidote for acetaminophen (paracetamol) overdose and has been explored for chronic liver diseases.

• Key evidence: A meta-analysis of 8 controlled clinical trials published in 2023 (ScienceDirect) examined NAC supplementation in NAFLD/MASLD patients.
• Critical finding: The meta-analysis found that NAC did not significantly improve ALT levels in human trials. It did show improvements in albumin and bilirubin levels, suggesting some benefit for liver synthetic function.
• Important caveat: Many positive findings attributed to NAC in MASLD (such as improvements in NAS scores or ALT) come from animal studies only and have not been replicated in human clinical trials. It is essential to distinguish animal data from human data when evaluating NAC for liver disease.
• Limitations: Small trial sizes, heterogeneous study designs, and the disconnect between animal and human results limit the strength of the evidence.

EMERGING with caveats — Mixed results in human trials. Improvements seen in albumin and bilirubin but not in liver transaminases. Do not rely on animal study data when evaluating this supplement.

Huaier (Trametes robiniophila Murr.) is a traditional Chinese medicinal fungus that has been studied as adjuvant therapy after curative treatment for hepatocellular carcinoma.

• Key evidence: A Phase IV randomized controlled trial enrolled 1,044 patients across 39 centers in China, randomized 2:1 to Huaier granule versus no treatment after curative hepatectomy for HCC. The study found a recurrence-free survival hazard ratio of 0.67 (95% CI: 0.55–0.81, p=0.0001), meaning a 33% reduction in risk of HCC recurrence in the Huaier group.
• Important limitation: This was an open-label trial — neither patients nor investigators were blinded to treatment assignment. Open-label designs can introduce bias, particularly in subjective outcome assessments and patient behavior. The lack of blinding is a significant caveat when interpreting the results.
• Context: Huaier granule is approved in China as an adjuvant therapy for HCC. It is not approved or available through standard channels in the United States or Europe.
• Source: PubMed 29802174.

EMERGING — Large trial with a significant recurrence-reduction signal, but open-label design limits confidence. Discuss with your oncology team if accessible.

Fuzheng Huayu (FZHY) is a traditional Chinese herbal formula composed of six herbs. It became the first traditional Chinese herbal formula to complete a US clinical trial for liver fibrosis.

• Key evidence: A Phase 2b, randomized, placebo-controlled, double-blinded, multicenter trial conducted at 8 US liver centers (including Stanford) enrolled 118 patients with chronic hepatitis C-related liver fibrosis. Of 82 patients with complete paired liver biopsies:
  • In the advanced fibrosis subgroup (Ishak F3/F4): 57% of FZHY-treated patients showed fibrosis regression compared to 37% on placebo.
• Significance: This was the first rigorous US clinical trial of a traditional Chinese herbal formula for liver fibrosis, using the gold-standard design (randomized, double-blind, placebo-controlled) and biopsy-confirmed endpoints.
• Limitations: The overall population result did not reach statistical significance — the signal was strongest in the advanced fibrosis subgroup. The trial population had hepatitis C (not MASH), so the results may not directly apply to MASLD patients. Sample size was modest.
• Source: PMC9307334.

EMERGING — Notable as the first US-based double-blind trial of a Chinese herbal formula for fibrosis. Encouraging signal in advanced fibrosis but not definitive in the overall population.

Sho-saiko-to (also known as Xiao Chai Hu Tang or TJ-9) is one of the most studied Kampo (Japanese traditional) herbal formulas. It has been investigated for its potential to reduce the development of hepatocellular carcinoma in patients with cirrhosis.

• Key evidence: A prospective randomized controlled study enrolled 260 patients with cirrhosis (mostly hepatitis B and C-related) in Japan.
• Critical finding: The primary analysis showed only a trend toward reduced HCC development (p=0.071) — this did not reach statistical significance. Statistical significance was reached only in the HBsAg-negative subgroup (p=0.024).
• Important limitation: This was an open-label trial (not blinded), which introduces potential bias. The overall primary endpoint was not met. The positive subgroup result must be interpreted cautiously, as subgroup analyses are hypothesis-generating, not confirmatory.
• Safety note: Sho-saiko-to has been associated with rare but serious interstitial pneumonitis, particularly when combined with interferon. It should not be used with interferon therapy.
• Source: PubMed 8625175.

EMERGING with strong caveats — Showed a trend toward HCC prevention but did not meet its primary endpoint. Open-label design and subgroup-dependent significance limit the strength of the evidence. Do not rely on this as a proven HCC prevention strategy.

Glycyrrhizin is the active compound in licorice root (Glycyrrhiza glabra). Its intravenous formulation, SNMC (Stronger Neo-Minophagen C), has been approved in Japan for the treatment of chronic hepatic diseases since the 1970s.

• Clinical use: SNMC has been widely used across Japan, China, Korea, Taiwan, and India for over 40 years as standard supportive therapy for chronic hepatitis. It is administered intravenously and has been used to reduce liver inflammation (ALT levels) in patients with chronic hepatitis B and C.
• Mechanism: Glycyrrhizin has anti-inflammatory, antiviral, and hepatoprotective properties. It inhibits hepatic inflammation and has been shown to reduce ALT levels in multiple studies.
• Limitations: Most evidence comes from observational studies and non-blinded trials. The drug requires intravenous administration (not an oral supplement). Glycyrrhizin can cause pseudoaldosteronism (hypertension, hypokalemia, edema) with prolonged use. Oral licorice supplements should not be considered equivalent to clinical-grade SNMC. It is not approved or widely available in the United States or Europe for this indication.

STANDARD (Japan/Asia) — Widely used in Japan for decades as standard supportive therapy for chronic hepatitis. Not part of Western guidelines.

Portal hypertension is the central problem in cirrhosis. Scar tissue blocks blood flow through the liver, causing pressure to build in the portal vein. This elevated pressure drives nearly every complication of cirrhosis: blood backs up into alternative channels (varices), fluid leaks into the abdomen (ascites), and the liver can no longer efficiently clear toxins from the blood (encephalopathy). Managing portal hypertension is the key to preventing decompensation.

Ascites is the accumulation of fluid in the abdominal cavity. It is the most common complication of cirrhosis and a defining feature of decompensation. Patients notice a gradually enlarging abdomen, weight gain, discomfort, and early fullness when eating.

Management: Sodium restriction (typically 2,000 mg or less per day), diuretics (spironolactone, often combined with furosemide), and in refractory cases, periodic paracentesis (draining the fluid with a needle) or TIPS placement. Spontaneous bacterial peritonitis (SBP) — infection of the ascites fluid — is a dangerous complication that requires prompt antibiotic treatment and often preventive antibiotics afterward.

When the liver cannot adequately clear ammonia and other toxins, they accumulate in the blood and affect brain function. Symptoms range from subtle personality changes, forgetfulness, and sleep disturbance (covert encephalopathy) to obvious confusion, disorientation, slurred speech, and in severe cases, coma.

Management: Lactulose (an osmotic laxative that traps ammonia in the gut for excretion) is the cornerstone treatment. Rifaximin (a non-absorbed antibiotic) is often added for prevention of recurrent episodes. The goal is 2–3 soft bowel movements per day. Protein restriction is no longer recommended — adequate protein (1.2–1.5 g/kg/day) is essential to prevent muscle wasting.

Portal hypertension causes blood to divert through thin-walled veins (varices) in the esophagus and stomach. These varices can rupture and cause massive, life-threatening gastrointestinal bleeding. Variceal bleeding is a medical emergency with significant mortality.

Prevention: Screening endoscopy to detect varices, non-selective beta-blockers (propranolol, nadolol, carvedilol) to reduce portal pressure, and endoscopic band ligation for large varices. Prevention is far more effective than treating an acute bleed.

• Jaundice: Yellowing of the skin and eyes occurs when the liver can no longer process bilirubin. Deepening jaundice is a sign of worsening liver function.
• Infections: Cirrhosis impairs the immune system. Patients are highly susceptible to infections, particularly spontaneous bacterial peritonitis, urinary tract infections, and pneumonia. Fever in a patient with cirrhosis should be treated as a medical emergency until proven otherwise.
• Hepatorenal syndrome: A form of kidney failure triggered by cirrhosis-related changes in blood flow. It is serious and may require treatment with vasoconstrictors, albumin, or ultimately transplant.
• Sarcopenia (muscle wasting): Cirrhosis causes progressive muscle loss, which worsens outcomes, reduces quality of life, and affects transplant eligibility. Adequate protein intake and regular exercise (even mild) are critical to combat this.

Every patient with cirrhosis should undergo HCC screening every 6 months. The standard protocol is:

• Liver ultrasound performed by an experienced operator
• AFP (alpha-fetoprotein) blood test

HCC caught by screening is more likely to be at an early, curable stage. Missing even one screening appointment can allow a tumor to grow beyond the window for curative treatment. This is one of the highest-impact things a patient with cirrhosis can do for their survival.

If ultrasound visualization is poor (common in obese patients or those with nodular livers), cross-sectional imaging with CT or MRI every 6 months may be considered as an alternative.

Treatment depends on the tumor size and number, underlying liver function, performance status, and whether the cancer has spread. The major options:

• Surgical resection: Removing the tumor and surrounding liver tissue. Best for patients with a single tumor and well-preserved liver function (compensated cirrhosis). Requires enough healthy liver to sustain function after surgery.
• Ablation (radiofrequency or microwave): Destroying small tumors (typically ≤3 cm) using heat delivered through a needle. Can be curative for small tumors and is less invasive than surgery.
• Liver transplant: The only treatment that cures both the cancer and the underlying cirrhosis. Best candidates have tumors within the Milan criteria (single tumor ≤5 cm, or up to 3 tumors each ≤3 cm) without vascular invasion or extrahepatic spread. HCC exception points provide priority on the transplant waiting list.
• TACE (transarterial chemoembolization): Delivering chemotherapy directly to the tumor through its blood supply, then blocking that blood supply. Used for intermediate-stage tumors not amenable to surgery or ablation.
• TARE / Y-90 (transarterial radioembolization): Delivering radioactive microspheres directly to the tumor through its arterial blood supply. Used for intermediate-stage or locally advanced HCC, and sometimes as a bridge to transplant.
• Systemic therapy: For advanced HCC not treatable with surgery or locoregional approaches. The current first-line standard is the combination of atezolizumab plus bevacizumab (immunotherapy plus anti-angiogenic), based on the IMbrave150 trial. Other options include durvalumab plus tremelimumab (HIMALAYA trial), lenvatinib, and sorafenib. Second-line options include cabozantinib, regorafenib, and ramucirumab (for AFP ≥400).

Transplant evaluation is typically considered when:

• Decompensated cirrhosis develops (ascites, variceal bleeding, encephalopathy, jaundice)
• MELD score reaches 15 or higher (the threshold where transplant benefit exceeds surgical risk)
• HCC is diagnosed within transplant criteria (Milan or extended criteria)
• Acute liver failure occurs
• Quality of life is severely impaired by liver disease complications despite optimal medical management

MASH/MASLD-related liver disease is now the leading or second-leading indication for liver transplant in the United States, reflecting the growing prevalence of metabolic liver disease.

Transplant evaluation is comprehensive and typically takes several weeks. It includes:

• Medical assessment: cardiac evaluation (echocardiogram, stress test, possibly cardiac catheterization), pulmonary function tests, cancer screening, infectious disease testing, dental evaluation
• Psychosocial evaluation: mental health assessment, social support assessment, substance use history
• Financial counseling: insurance review, medication costs (lifelong immunosuppression)
• Nutritional assessment and optimization
• Education about the transplant process, lifelong medication requirements, and post-transplant expectations

For patients with alcohol-related liver disease, most programs require a period of documented sobriety (traditionally 6 months, though this is evolving).

The MELD (Model for End-Stage Liver Disease) score is the system used to prioritize patients on the transplant waiting list. It is calculated from bilirubin, creatinine, and INR (a blood clotting measure), and it predicts 90-day mortality without transplant. Higher scores indicate greater urgency and receive priority. MELD-Na (which incorporates sodium) is the current version used for allocation.

Patients with HCC meeting criteria receive MELD exception points that give them priority on the list, recognizing that their MELD score may underestimate their urgency because cancer can progress while liver function is still relatively preserved.

A healthy adult can donate a portion of their liver to a patient in need. The donor’s liver regenerates to near-normal size within weeks. Living donor transplant can eliminate the wait for a deceased donor organ and allows the transplant to be planned electively. The donor evaluation is rigorous to ensure safety. Living donor transplant is performed at specialized centers and has excellent outcomes for both donor and recipient when performed by experienced teams.

Liver transplant has excellent long-term outcomes. One-year survival exceeds 90%, and many patients live 20 years or more with good quality of life. Key aspects of post-transplant life:

• Immunosuppression: Lifelong medications to prevent rejection. These require careful monitoring and carry risks of infection and certain cancers over time.
• Metabolic management: MASH can recur in the transplanted liver if the underlying metabolic risk factors are not addressed. Weight management, diabetes control, and cardiovascular risk reduction remain important after transplant.
• Follow-up: Regular clinic visits, blood work, and imaging, particularly frequent in the first year and then less often as time passes.
• Return to normal activities: Most transplant recipients return to work, exercise, travel, and lead full lives within 3–6 months of surgery.

A pre-pregnancy visit with your liver specialist (and, if you have cirrhosis or a transplant, a high-risk pregnancy doctor called a maternal-fetal-medicine specialist) is the single most valuable step. Things to sort out in advance:

• Review your medicines. Several liver-related medicines should be stopped or switched before pregnancy — this is much easier to do calmly ahead of time than urgently after a positive test (see the medicine list below).
• Know your stage. Simple fatty liver carries different risks than cirrhosis. Your team can explain what your specific situation means for pregnancy.
• If you have cirrhosis, ask about being checked for varices (swollen veins in the food pipe) before pregnancy — treating them in advance lowers the risk of bleeding later.
• If you’ve had a transplant, pregnancy is usually possible but generally recommended after the first 1–2 years once things are stable, and one anti-rejection medicine in particular (mycophenolate) must be switched before conceiving.

Never stop or change a medicine on your own — but here is the general picture to discuss with your team:

• Usually stopped before pregnancy: the MASH medicine resmetirom; weight-loss/GLP-1 injections such as semaglutide (stopped about 2 months before trying); the blood-pressure/fluid pill spironolactone; ACE-inhibitor and ARB blood-pressure medicines; and (in transplant patients) mycophenolate.
• Often continued, with monitoring: lactulose and rifaximin for confusion (hepatic encephalopathy); beta-blockers for varices; and, in transplant patients, tacrolimus and azathioprine.
• Statins are generally paused during pregnancy — discuss timing with your team.

The key message: bring a complete list of everything you take to your pre-pregnancy visit and ask, “Which of these do I need to change, and when?”

Fatty liver in pregnancy is increasingly common and is worth taking seriously: it is linked to higher chances of gestational diabetes, high blood pressure in pregnancy (including pre-eclampsia), and early delivery. The good news is that the main approach is managing those risks with your obstetric team — not liver medicines — and pregnancy can be a powerful motivator to build the healthy-eating and activity habits that help your liver for the long term. The MASH medicines are paused during pregnancy and can be restarted afterward (your team will advise about breastfeeding).

Pregnancy is less common with cirrhosis (fertility is often reduced) but it does happen, and it needs careful, specialist-led care. The main concern is that the extra blood volume of pregnancy raises the pressure in the liver’s veins, which can increase the risk of variceal bleeding — especially in the middle and later parts of pregnancy. That is exactly why screening for and treating varices before or early in pregnancy matters so much. With a coordinated team (liver specialist, high-risk pregnancy doctor, and anesthesiologist) and a clear delivery plan, many women with well-compensated cirrhosis have good outcomes — but the risks rise significantly with more advanced disease, which is why honest, individualized counseling beforehand is so important.

Reliable contraception is part of the plan — both to time pregnancy for when your medicines are safe, and because an unplanned pregnancy with advanced liver disease carries real risk. Estrogen-containing birth control (most combined pills) is usually avoided in active liver disease, cirrhosis, or a history of liver tumors. Progestin-only options and the hormonal IUD are generally preferred. Your team can help you choose what fits your specific situation.

Sometimes liver trouble appears for the first time in pregnancy and is unrelated to chronic liver disease. These are managed by your obstetric team, but it helps to know they exist:

• Intrahepatic cholestasis of pregnancy (ICP): intense itching (often hands and feet) in later pregnancy, caused by a buildup of bile acids. It is treated with a medicine called ursodeoxycholic acid and close monitoring of the baby.
• Pre-eclampsia / HELLP syndrome: high blood pressure with liver and blood-count changes — a serious condition where delivery is often the treatment.
• Acute fatty liver of pregnancy: a rare but serious late-pregnancy emergency requiring urgent delivery and specialist care.

Tell your doctor promptly about severe itching, yellowing of the skin or eyes, severe upper-abdominal pain, or feeling very unwell in pregnancy.

• Given my liver stage, what are the risks of pregnancy for me and the baby?
• Which of my medicines need to change before I try to conceive, and when?
• Do I need to be checked (or treated) for varices before pregnancy?
• Should I be seeing a high-risk pregnancy (maternal-fetal-medicine) specialist?
• (After transplant) How long should I wait, and do any of my anti-rejection medicines need changing?
• What birth control is safest for me right now?

The most powerful thing a caregiver can do is join the lifestyle changes rather than enforce them. When the whole household shifts to a Mediterranean diet, reduces sugar, and exercises together, the patient is far more likely to sustain the changes. This is not about policing — it is about partnership.

• Cook and eat the same meals. Do not maintain a separate “normal” kitchen.
• Walk, bike, or exercise together. Make it a shared routine, not a medical assignment.
• Remove temptation. If alcohol needs to go, it goes for the household, not just the patient.
• Celebrate milestones. Weight loss targets, improved lab values, and sustained sobriety deserve recognition.

• Help manage the medication schedule. Patients on lactulose, diuretics, and rifaximin need consistent timing.
• Monitor lactulose adherence — stopping it can be dangerous. If the patient is having too many or too few bowel movements, call the liver team rather than adjusting on your own.
• Keep a current medication list. Bring it to every appointment and emergency visit.
• Know which over-the-counter medications to avoid: NSAIDs (ibuprofen, naproxen, aspirin in high doses), acetaminophen above safe doses (discuss the limit with the liver team), and any supplement not approved by the hepatologist.

Caregivers are often the first to notice subtle changes. Know what to watch for:

• Confusion or personality changes: The earliest sign of hepatic encephalopathy may be subtle — the patient seems “not quite right,” is more forgetful, reverses sleep patterns, or has difficulty with tasks they normally handle easily. Trust your instincts and contact the liver team.
• Abdominal swelling: Track weight daily. A gain of 3+ pounds in a day or 5+ in a week suggests fluid accumulation.
• Yellow skin or eyes: Worsening jaundice means worsening liver function.
• Fever: In anyone with cirrhosis, fever is a medical emergency until proven otherwise.

If transplant is on the table, caregivers become logistics coordinators:

• The transplant team may call at any hour when an organ becomes available. Keep phones charged and accessible. Have a go-bag packed with essentials.
• Arrange transportation that can reach the transplant center within 2 hours of the call.
• Plan for 1–2 weeks in the hospital and 3–6 months of intensive recovery at home.
• The caregiver will need support during this period — arrange backup help in advance.

Caregiver burnout is real and common. You cannot pour from an empty cup.

• Schedule regular time off. This is maintenance, not luxury.
• Build a team — recruit other family members, friends, or home health aides to share the load.
• Attend to your own health. Keep your own medical appointments.
• Consider joining a caregiver support group (many transplant centers offer these).
• Ask the transplant or hepatology social worker about resources specifically for caregivers.

• What is my fibrosis stage? How was it determined, and how confident are we in that assessment?
• Do I have simple steatosis, MASH, or cirrhosis?
• What caused my liver disease? Have hepatitis B, hepatitis C, autoimmune hepatitis, and other causes been ruled out?
• What is my FIB-4 score?
• Should I get a FibroScan or MR elastography?
• What are my cardiovascular risk factors, and how are we addressing them?
• Am I a candidate for resmetirom or semaglutide?

• Has my fibrosis improved, stabilized, or worsened since the last assessment?
• Are my liver enzymes trending in the right direction?
• Am I due for liver cancer screening?
• Should any medications be adjusted based on my current liver function?
• Is my weight loss on track? Do I need additional support (dietitian, structured program, medication)?

• Is my cirrhosis compensated or decompensated?
• What is my MELD score?
• Am I on a 6-month HCC screening schedule?
• Have I been screened for varices? Do I need a beta-blocker?
• Should I be evaluated for liver transplant?
• What signs should prompt me to go to the emergency room?
• Am I on the right doses of lactulose and rifaximin?
• Am I getting enough protein? Should I see a dietitian?

• What stage is the cancer, and what staging system is being used?
• Am I a candidate for curative treatment (resection, ablation, transplant)?
• Has my case been discussed at a multidisciplinary tumor board?
• If transplant is an option, how do HCC exception points work?
• What locoregional or systemic therapies are appropriate?
• Are there clinical trials I should consider?
• Should I seek a second opinion at a major liver center?

Phone: 801-213-9797
Location: University of Utah Health Sciences Campus, Salt Lake City, UT

The University of Utah Liver Program provides comprehensive hepatology services including fibrosis staging, MASH treatment, cirrhosis management, and liver transplant evaluation. It is a leading liver transplant program in the Intermountain region. The hepatology team includes specialists in metabolic liver disease, viral hepatitis, autoimmune liver disease, and liver cancer.

Phone: 801-587-7000
Location: 2000 Circle of Hope Drive, Salt Lake City, UT 84112

NCI-designated Comprehensive Cancer Center for the Mountain West. For patients with HCC, Huntsman provides multidisciplinary liver tumor boards, interventional radiology (TACE, TARE/Y-90), surgical oncology, and medical oncology with access to clinical trials for liver cancer. Coordinates closely with the University of Utah transplant program.

• American Liver Foundation — education, support groups, helpline. 800-465-4837. liverfoundation.org
• American Association for the Study of Liver Diseases (AASLD) — clinical guidelines and patient resources. aasld.org
• UNOS (United Network for Organ Sharing) — transplant information and waiting list data. unos.org
• Fatty Liver Foundation — patient advocacy and education. fattyliverfoundation.org

Liver disease occupies an unusual position in medicine: it is one of the few serious organ diseases where the organ itself can genuinely heal. The liver’s regenerative capacity means that at every stage up to and including compensated cirrhosis, meaningful improvement is possible. This is not false optimism — it is biology.

For patients with early disease (stages 1–3), the honest message is straightforward: you have a real opportunity to reverse this. The tools exist — lifestyle change, medications, and close monitoring. The liver will do its part if you do yours.

For patients with cirrhosis, the message is more nuanced but still hopeful: stabilization is achievable, decompensation can often be prevented or managed, liver cancer can be caught early with screening, and transplant offers a genuine second chance when needed. Transplant outcomes are excellent, with most recipients returning to full, active lives.

For patients with liver cancer, the message depends on stage — but early HCC caught by screening has curative options, and even advanced HCC has more treatment options today than at any point in history.

For some patients, the disease progresses despite treatment, transplant is not an option, or the cancer is beyond curative therapy. In these situations, palliative care — specialized care focused on comfort, symptom management, and quality of life — becomes the most important treatment. Choosing hospice when the time comes is not giving up; it is choosing to spend remaining time as well as possible, supported by a team dedicated to that goal.

These conversations are hard but important. Most families describe relief, not regret, after having them openly.

• Resmetirom (Rezdiffra): Conditionally approved by the FDA in March 2024 for non-cirrhotic MASH with moderate to advanced fibrosis (F2–F3), in conjunction with diet and exercise. This was the first drug ever approved specifically for MASH. Full approval depends on confirmatory trial data expected by approximately 2028.
• Semaglutide (Wegovy/Ozempic): Approved for obesity (Wegovy, 2.4 mg weekly) and type 2 diabetes (Ozempic, up to 2 mg weekly). A specific MASH indication is under regulatory review following the ESSENCE trial results.
• HCC systemic therapy: Atezolizumab plus bevacizumab (Tecentriq + Avastin) and durvalumab plus tremelimumab (Imfinzi + a single priming dose of tremelimumab) are both first-line options for advanced HCC.

• Resmetirom: Under regulatory review by the EMA as of mid-2026. Not yet approved in the EU or UK.
• Semaglutide: Approved in the EU and UK for obesity and type 2 diabetes. A MASH-specific indication has not yet been approved.
• EASL guidelines: The European Association for the Study of the Liver (EASL), together with EASD and EASO, updated clinical practice guidelines in 2024 adopting the MASLD/MASH nomenclature and providing detailed management pathways broadly aligned with AASLD guidance.
• HCC therapy: Atezolizumab plus bevacizumab and durvalumab plus tremelimumab are both available as first-line systemic options, consistent with US practice.

• Resmetirom: Not approved in Japan as of mid-2026.
• Semaglutide: Approved for type 2 diabetes and obesity. Not approved specifically for MASH.
• Glycyrrhizin (Stronger Neo-Minophagen C / SNMC): Used as standard supportive therapy for chronic liver disease in Japan for over 40 years. Administered intravenously in hepatology clinics. Not approved or commonly available in the US or Europe.
• Sho-saiko-to (TJ-9): A traditional Kampo herbal formula studied for liver fibrosis and HCC prevention in cirrhotic patients. Used clinically in Japan, though evidence for HCC prevention did not reach statistical significance in the primary trial analysis.
• HCC therapy: Lenvatinib is widely used as first-line systemic therapy for HCC in Japan, in addition to immunotherapy combinations. Hepatic arterial infusion chemotherapy (HAIC) is more commonly used than in Western countries.

• Resmetirom: Not approved in Canada as of mid-2026. Canadian patients may access it through clinical trials or special access programs.
• Semaglutide: Approved for obesity and type 2 diabetes. A MASH indication has not been approved.
• Canadian Association for the Study of the Liver (CASL): CASL guidelines are broadly aligned with AASLD guidance and have adopted the MASLD/MASH nomenclature.
• HCC therapy: Standard systemic options (atezolizumab plus bevacizumab, durvalumab plus tremelimumab) are available, though provincial formulary coverage may vary.

• Australia (TGA): Resmetirom is not approved. Semaglutide is approved for obesity and type 2 diabetes. HCC systemic therapies are generally available through the Pharmaceutical Benefits Scheme (PBS).
• China: MASLD prevalence is rising rapidly. Resmetirom is not approved. Huaier granule (an herbal extract) has been studied in a Phase IV trial of 1,044 HCC patients and is used post-resection in some centers. Lenvatinib and HAIC are commonly used for HCC. The ORIENT-32 trial tested sintilimab plus bevacizumab biosimilar for HCC in a Chinese population.
• India: MASLD prevalence is high and growing. Access to newer therapies is limited outside major academic centers. Living donor liver transplantation is well established. The Indian National Association for Study of the Liver (INASL) publishes its own guidelines.

Regulatory approvals change frequently. Always check with your medical team or the relevant national regulatory authority for the most current information in your country.

• AFP (alpha-fetoprotein) — a blood test used as part of liver cancer screening. Elevated levels may suggest HCC.
• Ascites — accumulation of fluid in the abdominal cavity, a common complication of decompensated cirrhosis.
• Ballooning — swelling and damage to liver cells, a hallmark feature of MASH on biopsy.
• BCLC (Barcelona Clinic Liver Cancer) — the most widely used staging system for HCC, guiding treatment decisions.
• Cirrhosis — extensive scarring of the liver (F4 fibrosis) with disruption of normal architecture. Subdivided into compensated and decompensated.
• Compensated cirrhosis — cirrhosis where the liver is still functioning adequately and major complications have not yet appeared.
• Decompensated cirrhosis — cirrhosis with complications: ascites, variceal bleeding, encephalopathy, or jaundice.
• FIB-4 — a simple fibrosis screening score calculated from age, platelet count, AST, and ALT.
• FibroScan — a non-invasive device that measures liver stiffness (a marker of fibrosis) and liver fat (CAP score).
• Fibrosis — scar tissue in the liver, staged F0 (none) through F4 (cirrhosis).

• GLP-1 receptor agonist — a class of drugs (including semaglutide) that reduce appetite, promote weight loss, and improve insulin sensitivity.
• HCC (hepatocellular carcinoma) — the most common type of primary liver cancer, usually arising in the setting of cirrhosis.
• Hepatic encephalopathy — confusion and cognitive impairment caused by the buildup of ammonia and other toxins when the liver cannot clear them.
• Hepatologist — a gastroenterologist with specialized training and focus on liver disease.
• Lactulose — an osmotic laxative that traps ammonia in the gut for excretion; the cornerstone treatment for hepatic encephalopathy.
• MASLD — Metabolic Dysfunction-Associated Steatotic Liver Disease; the new name for NAFLD.
• MASH — Metabolic Dysfunction-Associated Steatohepatitis; the new name for NASH. The inflammatory form of fatty liver disease.
• MELD score — Model for End-Stage Liver Disease; a score predicting 90-day mortality, used to prioritize patients on the transplant waiting list.
• MetALD — the overlap category for liver disease driven by both metabolic factors and moderate alcohol intake.
• Milan criteria — transplant eligibility criteria for HCC: single tumor ≤5 cm, or up to 3 tumors each ≤3 cm, without vascular invasion.
• MR elastography (MRE) — an MRI-based technique for measuring liver stiffness; the most accurate non-invasive fibrosis staging tool.

• NAS (NAFLD Activity Score) — a histologic scoring system grading steatosis, lobular inflammation, and ballooning on liver biopsy.
• Paracentesis — a procedure to drain ascites fluid from the abdomen using a needle.
• Portal hypertension — elevated pressure in the portal vein caused by impaired blood flow through a scarred liver; drives most complications of cirrhosis.
• Resmetirom (Rezdiffra) — a thyroid hormone receptor beta agonist; the first drug approved specifically for MASH with fibrosis.
• Rifaximin — a non-absorbed antibiotic used with lactulose to prevent recurrent hepatic encephalopathy.
• Sarcopenia — progressive muscle wasting, common in cirrhosis and associated with worse outcomes.
• SBP (spontaneous bacterial peritonitis) — infection of ascites fluid; a medical emergency requiring prompt antibiotics.
• Semaglutide (Wegovy/Ozempic) — a GLP-1 receptor agonist approved for MASH with fibrosis, also used for obesity and type 2 diabetes.
• Steatosis — the accumulation of fat within liver cells.
• TACE — transarterial chemoembolization; a locoregional treatment for HCC delivering chemotherapy and blocking tumor blood supply.
• TARE / Y-90 — transarterial radioembolization; a locoregional treatment delivering radioactive microspheres to liver tumors.
• THR-β agonist — thyroid hormone receptor beta agonist; the drug class of resmetirom.
• TIPS — transjugular intrahepatic portosystemic shunt; a procedure creating a channel within the liver to reduce portal pressure.
• Varices — enlarged, fragile veins (usually in the esophagus or stomach) caused by portal hypertension; can rupture and cause life-threatening bleeding.

• AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (updated nomenclature: MASLD/MASH)
• EASL Clinical Practice Guidelines on the management of non-alcoholic fatty liver disease
• AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
• AASLD/EASL consensus statement on the new nomenclature of steatotic liver disease (2023)
• Harrison SA, et al. Resmetirom for MASH with liver fibrosis (MAESTRO-NASH). New England Journal of Medicine. 2024.
• Loomba R, et al. Semaglutide for MASH with liver fibrosis (ESSENCE). New England Journal of Medicine. 2024.
• Sanyal AJ, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis (PIVENS). New England Journal of Medicine. 2010.
• Finn RS, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma (IMbrave150). New England Journal of Medicine. 2020.
• REGENERATE trial (obeticholic acid), STEP trials (semaglutide for obesity), and other ongoing studies informing the field.

International and emerging research sources (added May 2026):

• Berberine meta-analysis: Wei X, et al. Journal of Translational Medicine. 2024. PMC10908013. (10 RCTs, 811 patients)
• Silymarin meta-analysis: Kalopitas G, et al. Annals of Hepatology. 2023. PubMed 38579127. (26 RCTs, 2,375 patients)
• Huaier granule Phase IV RCT: Chen Q, et al. Gut. 2018. PubMed 29802174. (1,044 patients, 39 centers)
• Fuzheng Huayu US Phase II trial: Liu CH, et al. Hepatology. 2022. PMC9307334. (118 patients, 8 US centers)
• Sho-saiko-to for HCC prevention: Oka H, et al. Cancer. 1995. PubMed 8625175. (260 cirrhotic patients)
• Probiotics for NAFLD: Frontiers in Nutrition. 2024. fnut.2024.1470185. (37 RCTs, 1,921 patients)
• NAC for NAFLD meta-analysis: ScienceDirect. 2023. (8 controlled clinical trials)
• Artichoke leaf extract: Rangboo V, et al. 2016. (60 NASH patients, double-blind RCT)

This is a representative list, not exhaustive. For the full evidence base behind any specific recommendation, consult the cited guidelines or ask your hepatologist.